CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, today announced the online availability of three abstracts that will be presented during the April 18-22 American Association of Cancer Research (AACR) Annual Meeting in Philadelphia. The abstracts were published online at www.aacr.org. "We are very pleased with the high quality of our data being presented at